Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression

Journal of Physiology

Volumn 593, Issue 5, 2015, Pages 1239-1257

  Mallinson, Joanne E ^a   Marimuthu, Kanagaraj ^a   Murton, Andrew ^a   Selby, Anna ^a   Smith, Kenneth ^a   Constantin Teodosiu, Dumitru ^a   Rennie, Michael J ^a   Greenhaff, Paul L ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ATORVASTATIN; CREATINE; CREATINE PHOSPHATE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MESSENGER RNA; MUSCLE PROTEIN; PYRUVATE DEHYDROGENASE; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ABDOMINAL OBESITY; AGED; AMINOACIDEMIA; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXTENSOR MUSCLE; FOOD INTAKE; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNEE; MALE; MUSCLE BIOPSY; MUSCLE ISOMETRIC CONTRACTION; MUSCLE MASS; MUSCLE STRENGTH; MYALGIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; CASE CONTROL STUDY; GENETICS; METABOLISM; MUSCLE CONTRACTION; MUSCLE WEAKNESS; PATHOPHYSIOLOGY; REACTION TIME;

AGED; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; CASE-CONTROL STUDIES; HUMANS; INSULIN RESISTANCE; MALE; MUSCLE CONTRACTION; MUSCLE PROTEINS; MUSCLE STRENGTH; MUSCLE WEAKNESS; REACTION TIME; RNA, MESSENGER; SIMVASTATIN;

EID: 84923611588     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.285577     Document Type: Article

References (54)

1. Abramson JD, Rosenberg HG, Jewell N & Wright JM (2013). Should people at low risk of cardiovascular disease take a statin? BMJ 347, f6123.
2. Bergouignan A, Rudwill F, Simon C & Blanc S (2011). Physical inactivity as the culprit of metabolic inflexibility: evidence from bed-rest studies. J Appl Physiol 111, 1201-1210.
3. Bergstrom J (1975). Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest 35, 609-616.
4. Bigland B & Lippold OC (1954). The relation between force, velocity and integrated electrical activity in human muscles. J Physiol 123, 214-224.
5. Blair SN, Sallis RE, Hutber A & Archer E (2012). Exercise therapy - the public health message. Scand J Med Sci Sports 22, e24-28.
6. Bonala S, Lokireddy S, McFarlane C, Patnam S, Sharma M & Kambadur R (2014). Myostatin induces insulin resistance via Casitas B-lineage lymphoma b (Cblb)-mediated degradation of insulin receptor substrate 1 (IRS1) protein in response to high calorie diet intake. J Biol Chem 289, 7654-7670.
7. Bouitbir J, Charles AL, Rasseneur L, Dufour S, Piquard F, Geny B & Zoll J (2011). Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol 111, 1477-1483.
8. Breen L, Stokes KA, Churchward-Venne TA, Moore DR, Baker SK, Smith K, Atherton PJ & Phillips SM (2013). Two weeks of reduced activity decreases leg lean mass and induces "anabolic resistance" of myofibrillar protein synthesis in healthy elderly. J Clin Endocrinol Metab 98, 2604-2612.
9. Bruckert E, Hayem G, Dejager S, Yau C & Begaud B (2005). Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 19, 403-414.
10. Burd NA, West DW, Staples AW, Atherton PJ, Baker JM, Moore DR, Holwerda AM, Parise G, Rennie MJ, Baker SK & Phillips SM (2010). Low-load high volume resistance exercise stimulates muscle protein synthesis more than high-load low volume resistance exercise in young men. PloS One 5, e12033.
11. Constantin-Teodosiu D, Cederblad G & Hultman E (1991). A sensitive radioisotopic assay of pyruvate dehydrogenase complex in human muscle tissue. Anal Biochem 198, 347-351.
12. Constantin D, McCullough J, Mahajan RP & Greenhaff PL (2011). Novel events in the molecular regulation of muscle mass in critically ill patients. J Physiol 589, 3883-3895.
13. DeFronzo RA, Tobin JD & Andres R (1979). Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237, E214-223.
14. Fuzi M, Palicz Z, Vincze J, Cseri J, Szombathy Z, Kovacs I, Olah A, Szentesi P, Kertai P, Paragh G & Csernoch L (2012). Fluvastatin-induced alterations of skeletal muscle function in hypercholesterolaemic rats. J Muscle Res Cell Motil 32, 391-401.
15. Gallen IW & Macdonald IA (1990). Effect of two methods of hand heating on body temperature, forearm blood flow, and deep venous oxygen saturation. Am J Physiol 259, E639-643.
16. Greenhaff PL, Karagounis LG, Peirce N, Simpson EJ, Hazell M, Layfield R, Wackerhage H, Smith K, Atherton P, Selby A & Rennie MJ (2008). Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 295, E595-604.
17. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC & Stone NJ (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44, 720-732.
18. Harris R, Hultman E & Nordesjo LO (1974). Glycogen, glycogen intermediates and high-energy phosphates determined in biopsy samples of musculus quadriceps femoris of man at rest. Methods and variance of values. Scand J Clin Lab Invest 33, 109-120.
19. Johnson BL, Adamczyk JW, Tennoe KO & Stromme SB (1976). A comparison of concentric and eccentric muscle training. Med Sci Sports 8, 35-38.
20. Kellis E & Baltzopoulos V (1998). Muscle activation differences between eccentric and concentric isokinetic exercise. Med Sci Sports Exerc 30, 1616-1623.
21. Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ, Koh Y & Shin EK (2008). Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 31, 776-782.
22. Kohrt WM, Kirwan JP, Staten MA, Bourey RE, King DS & Holloszy JO (1993). Insulin resistance in aging is related to abdominal obesity. Diabetes 42, 273-281.
23. Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, Lutjohann D, Smet J, VanCoster R, Seppanen-Laakso T, Lehtimaki T, Soini J & Oresic M (2006). A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 1, e97.
24. Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H, Nielsen LB, Helge JW & Dela F (2013). Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 61, 44-53.
25. Lee DS, Markwardt S, Goeres L, Lee CG, Eckstrom E, Williams C, Fu R, Orwoll E, Cawthon PM, Stefanick ML, Mackey D, Bauer DC & Nielson CM (2014). Statins and physical activity in older men: the osteoporotic fractures in men study. JAMA Intern Med 174, 1263-1270.
26. Lee SJ & McPherron AC (2001). Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A 98, 9306-9311.
27. Mallinson JE, Constantin-Teodosiu D, Glaves PD, Martin EA, Davies WJ, Westwood FR, Sidaway JE & Greenhaff PL (2012). Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents. J Physiol 590, 6389-6402.
28. Mallinson J, Constantin-Teodosiu D, Sidaway J, Westwood FR & Greenhaff P (2009). Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol 587, 219-230.
29. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D, Feng Q, Rieder MJ, Chen YD, Rotter JI, Ridker PM, Hopewell JC, Parish S, Armitage J, Collins R, Wilke RA, Nickerson DA, Stephens M & Krauss RM (2013). A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502, 377-380.
30. Mayhew TP, Rothstein JM, Finucane SD & Lamb RL (1995). Muscular adaptation to concentric and eccentric exercise at equal power levels. Med Sci Sports Exerc 27, 868-873.
31. McClure DL, Valuck RJ, Glanz M & Hokanson JE (2007). Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 16, 132-143.
32. Melzack R (1975). The short-form McGill pain questionnaire. Pain 30, 191-197.
33. Naci H & Loannidis J (2013). Comparative effectiveness of exercise and drug interventions on mortality outcome: metaepidemiological study. Br Med J 347.
34. Olsen RH, Krogh-Madsen R, Thomsen C, Booth FW & Pedersen BK (2008). Metabolic responses to reduced daily steps in healthy nonexercising men. JAMA 299, 1261-1263.
35. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM & Thompson PD (2012). Effect of statins on skeletal muscle function. Circulation 127, 96-103.
36. Ploquin C, Chabi B, Fouret G, Vernus B, Feillet-Coudray C, Coudray C, Bonnieu A & Ramonatxo C (2012). Lack of myostatin alters intermyofibrillar mitochondria activity, unbalances redox status, and impairs tolerance to chronic repetitive contractions in muscle. Am J Physiol Endocrinol Metab 302, E1000-1008.
37. Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJP, deLemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N & Ray KK (2011). Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 305, 2556-2564.
38. Reardon KA, Davis J, Kapsa RM, Choong P & Byrne E (2001). Myostatin, insulin-like growth factor-1, and leukemia inhibitory factor mRNAs are upregulated in chronic human disuse muscle atrophy. Muscle Nerve 24, 893-899.
39. Rennie MJ, Edwards RH, Halliday D, Matthews DE, Wolman SL & Millward DJ (1982). Muscle protein synthesis measured by stable isotope techniques in man: the effects of feeding and fasting. Clin Sci (Lond) 63, 519-523.
40. Schlattner U, Tokarska-Schlattner M & Wallimann T (2006). Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 1762, 164-180.
41. Scott D, Blizzard L, Fell J & Jones G (2009). Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 102, 625-633.
42. Sinzinger H & O'Grady J (2003). Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 57, 525-528.
43. Stadhouders AM, Jap PH, Winkler HP, Eppenberger HM & Wallimann T (1994). Mitochondrial creatine kinase: a major constituent of pathological inclusions seen in mitochondrial myopathies. Proc Natl Acad Sci U S A 91, 5089-5093.
44. Stephens FB, Wall BT, Marimuthu K, Shannon CE, Constantin-Teodosiu D, Macdonald IA & Greenhaff PL (2013). Skeletal muscle carnitine loading increases energy expenditure, modulates fuel metabolism gene networks and prevents body fat accumulation in humans. J Physiol 591, 4655-4666.
45. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MCW, Tzoulaki I, Buxbaum SG, vander A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, deFaire U, Veglia F, Ford I, Jukema JW, Westendorp RGJ, deBorst GJ, deJong PA, Algra A, Spiering W, der Zee AHM-v, Klungel OH, deBoer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJV, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SRK, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WMM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, vander Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD & Sattar N (2014). HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet doi: 10.1016/S0140-6736(14)61183-1.
46. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J & Guyton JR (1997). Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46, 1206-1210.
47. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S & Glass DJ (2009). Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 296, C1258-1270.
48. Tudor-Locke C, Washington TL & Hart TL (2009). Expected values for steps/day in special populations. Prev Med 49, 3-11.
49. Urso ML, Clarkson P, Hittel D, Hoffman EP & Thompson PD (2005). Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 25, 2560-2566.
50. Vaughan CJ & Gotto AM (2004). Update on statins 2003. Circulation 110, 886-892.
51. Wen CP, Wai JPM, Tsai MK, Yang YC, Cheng TYD, Lee M-C, Chan HT, Tsao CK, Tsai SP & Wu X (2011). Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 378, 1244-1253.
52. WHO (2010). World Health Statistics 2010. World Health Organisation, Geneva.
53. Zhang C, McFarlane C, Lokireddy S, Bonala S, Ge X, Masuda S, Gluckman PD, Sharma M & Kambadur R (2011). Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia 54, 1491-1501.
54. Zörgiebel T, Weigl L, Genth H & Hohenegger M (2007). Activation of RhoB in simvastatin-induced apoptosis of differentiated human skeletal muscle cells. BMC Pharmacol 7, 1-1.